Printer Friendly

MARION MERRELL DOW BOARD OF DIRECTORS NOMINATES JUDITH A. HEMBERGER, PH.D., TO BOARD

 KANSAS CITY, Mo., Feb. 18 /PRNewswire/ -- The board of directors of Marion Merrell Dow Inc. (NYSE: MKC) today nominated Judith A. Hemberger, Ph.D., to become a member of the board. Hemberger is vice resident, Global Regulatory and Medical Affairs, of the company. The nomination was approved by the board of directors at its meeting today and will be submitted to shareholders for a vote at the annual meeting in May.
 Immediately prior to assuming her present position in January 1992, Hemberger was corporate vice president of Regulatory Affairs and Scientific Communications of Marion Merrell Dow. She joined Marion Laboratories Inc., a predecessor company to Marion Merrell Dow, in 1979 as a clinical research associate. She advanced to senior clinical research associate in 1980; was promoted to manager, Clinical Research, in 1981; became director, Professional Education/Scientific Communications, in 1983; and was promoted to vice president, Regulatory Affairs and Scientific Communications, in 1986.
 Hemberger graduated cum laude with a major in biology and a minor in chemistry from Mount St. Scholastica College and earned her doctorate in pharmacology at the University of Missouri-Kansas City. She received her Masters of Business Administration from Rockhurst College in 1986. She was appointed to serve as a Regent of Rockhurst College in April 1991. In September 1991, Hemberger received the Alumni Achievement Award from the University of Missouri-Kansas City School of Pharmacy. Hemberger was elected to the board of directors of Benedictine College in June 1992.
 Hemberger was nominated to the board of Marion Merrell Dow under a policy implemented in 1992, which allows senior-management associates to rotate onto the board in an effort to broaden participation of the company's executives with the board. If elected, she will serve one year as a director, followed by one year as an advisory director. R. Malcolm Barbour, senior vice president, Strategic Development, who was elected to the board in May 1992, moves to advisory director this May. Walter M. Lovenberg, Ph.D., executive vice president, R & D Strategy and Scientific Affairs, has been an advisory director since May 1992 and will move off the board following the annual meeting.
 Marion Merrell Dow is a research-based global pharmaceutical organization dedicated to improving the longevity and quality of human life. The company is involved in the discovery, development, manufacture and sale of pharmaceutical products worldwide. In 1992, Marion Merrell Dow had sales of $3.3 billion and invested $465 million in Research and Development.
 -0- 2/18/93
 /CONTACT: David M. Thompson or Richard M. Johnson, of Marion Merrell Dow, 816-966-4000/
 (MKC)


CO: Marion Merrell Dow Inc. ST: Missouri IN: MTC SU: PER

MC -- DV004 -- 7849 02/18/93 11:26 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 18, 1993
Words:444
Previous Article:MUELLER INDUSTRIES ANNOUNCES FOURTH QUARTER AND YEAR END RESULTS
Next Article:FLORIDA POWER CORPORATION JOINS SUNSHINE PROJECT AS EQUITY PARTNER
Topics:


Related Articles
MARION MERRELL DOW NAMES NEW HEAD OF RESEARCH AND DEVELOPMENT
MARION MERRELL DOW PROPOSES THREE NEW MEMBERS TO JOIN ITS BOARD OF DIRECTORS
SHAREHOLDERS OF MARION MERRELL DOW ELECT DIRECTORS, HEAR PERFORMANCE UPDATE
MARION MERRELL DOW ANNOUNCES PLANS FOR TRANSITION IN SENIOR MANAGEMENT
MARION MERRELL DOW INC. BOARD OF DIRECTORS NOMINATES PETER W. LADELL TO BOARD
MARION MERRELL DOW INC. HOLDS ANNUAL MEETING, LONG-TERM FUTURE IS MAIN TOPIC OF DISCUSSION
KEITH R. MCKENNON NAMED TO BOARD OF DIRECTORS OF MARION MERRELL DOW INC.
MARION MERRELL DOW INC. BOARD OF DIRECTORS NOMINATES CHRISTIAN M. ERTLE TO BOARD
JUDITH A. HEMBERGER, PH.D., TO LEAD DRUG REGULATORY AFFAIRS FOR HOECHST MARION ROUSSEL
FRANK L. DOUGLAS, PH.D., M.D., TO LEAD RESEARCH FOR HOECHST MARION ROUSSEL

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters